Mizuho restated their buy rating on shares of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) in a report released on Thursday morning. The firm currently has a $87.00 price target on the stock.

“We do not view quarterly earnings as an important performance measure of companies like Aerie as valuation is primarily driven by progress of the R&D pipeline.”,” Mizuho’s analyst commented.

A number of other research firms also recently commented on AERI. Guggenheim assumed coverage on shares of Aerie Pharmaceuticals in a research note on Monday, October 23rd. They set a buy rating and a $80.00 price objective for the company. Zacks Investment Research upgraded shares of Aerie Pharmaceuticals from a sell rating to a hold rating in a research note on Tuesday, October 24th. Needham & Company LLC reiterated a buy rating and issued a $76.00 target price (up from $65.00) on shares of Aerie Pharmaceuticals in a research note on Monday, October 16th. Canaccord Genuity reiterated a positive rating and issued a $73.00 target price (up from $65.00) on shares of Aerie Pharmaceuticals in a research note on Monday, October 16th. Finally, BidaskClub upgraded shares of Aerie Pharmaceuticals from a strong sell rating to a sell rating in a research note on Monday, July 24th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and twelve have issued a buy rating to the company’s stock. The company currently has a consensus rating of Buy and an average target price of $70.93.

Aerie Pharmaceuticals (AERI) traded up $0.25 during trading on Thursday, hitting $62.00. 324,800 shares of the stock were exchanged, compared to its average volume of 526,963. Aerie Pharmaceuticals has a one year low of $35.20 and a one year high of $66.25. The company has a debt-to-equity ratio of 0.78, a current ratio of 15.24 and a quick ratio of 15.24.

COPYRIGHT VIOLATION WARNING: This article was published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this article on another domain, it was stolen and republished in violation of U.S. and international trademark & copyright legislation. The correct version of this article can be accessed at https://theolympiareport.com/2017/11/13/aerie-pharmaceuticals-aeri-buy-rating-reaffirmed-at-mizuho.html.

A number of hedge funds have recently modified their holdings of AERI. BlackRock Inc. lifted its position in Aerie Pharmaceuticals by 113,376.8% during the first quarter. BlackRock Inc. now owns 2,600,888 shares of the company’s stock worth $117,951,000 after acquiring an additional 2,598,596 shares during the last quarter. Vanguard Group Inc. lifted its position in Aerie Pharmaceuticals by 55.0% during the second quarter. Vanguard Group Inc. now owns 2,158,825 shares of the company’s stock worth $113,446,000 after acquiring an additional 766,300 shares during the last quarter. Senzar Asset Management LLC acquired a new stake in Aerie Pharmaceuticals during the second quarter worth approximately $20,568,000. Broadfin Capital LLC acquired a new stake in Aerie Pharmaceuticals during the second quarter worth approximately $16,291,000. Finally, AXA acquired a new stake in Aerie Pharmaceuticals during the second quarter worth approximately $10,961,000. Hedge funds and other institutional investors own 95.71% of the company’s stock.

About Aerie Pharmaceuticals

Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan).

Analyst Recommendations for Aerie Pharmaceuticals (NASDAQ:AERI)

Receive News & Ratings for Aerie Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.